NICE guidance recommends HeartFlow FFRct Analysis to help determine cause of stable chest pain in patients

NICE guidance recommends HeartFlow FFRct Analysis to help determine cause of stable chest pain in patients

Press releases may be edited for formatting or style | February 13, 2017 Cardiology Emergency Medicine

“The NICE guidance reinforces the value of the HeartFlow Analysis and affirms this technology can improve the way coronary artery disease is diagnosed and treated,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “We appreciate NICE’s thorough review of HeartFlow’s technology and believe their detailed assessment will be a valuable resource for providers and payers seeking to improve patient care.”

Coronary artery disease, also called coronary heart disease, is the leading cause of death for both men and women around the world. Coronary artery disease develops when the arteries leading to the heart narrow, often because plaque builds up in the vessel walls. Narrowing of the arteries can reduce blood flow to the heart, causing chest pain, heart attacks and death. Coronary artery disease is also one of the costliest medical diseases in the world today.

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.


For more information about the HeartFlow FFRct Analysis and centers that offer the technology, please call 0800 031 5265 or email info-uk@heartflow.com.


About HeartFlow Inc.
HeartFlow, Inc. is a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow FFRct Analysis is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy and physiology. The solution, which leverages deep learning to create a personalized 3D model of the patient’s arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience and reduce the cost of care. The HeartFlow FFRct Analysis is available in the United States, Canada, Europe and Japan. For more information visit heartflow.com/uk.

Back to HCB News

You Must Be Logged In To Post A Comment